Australian public assessment report for ezetimibe and ...

There were no significant differences between rosuvastatin (5 or 10 mg) + ezetimibe 10 mg and rosuvastatin (10 or 20 mg) with respect to the percentage of patients with gastrointestinal (GI) related, allergic reactions or rash, and hepatitis related AEs, elevations in ALT or AST ≥ 3x ULN or CK elevations ≥ 10x ULN. ................
................